Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Depreciation & Amortization (CF) (2016 - 2025)

Cytosorbents' Depreciation & Amortization (CF) history spans 15 years, with the latest figure at $97000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $97000.0 for Q4 2025, down 37.01% from a year ago — trailing twelve months through Dec 2025 was -$302497.0 (down 29.99% YoY), and the annual figure for FY2025 was $1.2 million, down 7.57%.
  • Depreciation & Amortization (CF) for Q4 2025 was $97000.0 at Cytosorbents, up from -$364000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $407208.0 in Q3 2023 to a low of -$404000.0 in Q2 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $215983.5 (2021), against an average of $126902.7.
  • The sharpest move saw Depreciation & Amortization (CF) soared 91.11% in 2023, then tumbled 199.76% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $214402.0 in 2021, then grew by 4.11% to $223214.0 in 2022, then soared by 75.29% to $391269.0 in 2023, then tumbled by 60.64% to $154000.0 in 2024, then crashed by 37.01% to $97000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $97000.0, -$364000.0, and -$404000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.